Checkit has released an upbeat H1 trading update that shows ARR continues to build rapidly – up 48% y/y to £10.2m, and so represents another strong period, after +43% ARR growth in FY22. The successful rollout of prior year wins - most notably: Grifols - a multinational pharmaceutical (worth £2.7m/3yrs) has been a key contributor. Meanwhile, further benefitting, CKT has also continued to ink new deals, for instance – expanding its role with Center Parcs (announced in May) and as well, Octapharma ....
11 Aug 2022
Robust ARR growth - tracking in line, cash still strong
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Robust ARR growth - tracking in line, cash still strong
Checkit plc (CKT:LON) | 22.0 0.2 4.8% | Mkt Cap: 23.8m
- Published:
11 Aug 2022 -
Author:
Harold Evans -
Pages:
3
Checkit has released an upbeat H1 trading update that shows ARR continues to build rapidly – up 48% y/y to £10.2m, and so represents another strong period, after +43% ARR growth in FY22. The successful rollout of prior year wins - most notably: Grifols - a multinational pharmaceutical (worth £2.7m/3yrs) has been a key contributor. Meanwhile, further benefitting, CKT has also continued to ink new deals, for instance – expanding its role with Center Parcs (announced in May) and as well, Octapharma ....